Cipla, one of India’s leading pharmaceutical companies, reported a 10% rise in profit for the April–June quarter of 2025. The company earned a net profit of ₹1,298 crore, up from ₹1,178 crore in the same period last year.
The total revenue from business operations grew to ₹6,957 crore in the first quarter of FY26, compared to ₹6,694 crore a year ago. This growth was mainly driven by strong demand in India and African markets.
Cipla’s Managing Director and Global CEO, Umang Vohra, said that their “One-India” strategy saw a 6% year-on-year growth. He added that Cipla’s key prescription medicines did better than the overall market, and their generic medicines business is growing again. The company’s consumer health products also continued to lead in the market.
Also See: AstraZeneca’s Eco-Friendly Inhaler for Smoker’s Lung Gets EU Panel Approval
Looking ahead, Vohra said Cipla will focus on growing in important markets, building its top brands, investing in future medicines, and resolving regulatory matters.
Here’s a breakdown of Cipla’s performance in different markets:
- India: Sales increased to ₹3,070 crore from ₹2,898 crore last year.
- North America: Sales dropped 7% to ₹1,933 crore due to pricing issues and product changes.
- Africa: Sales jumped 14% to ₹871 crore from ₹766 crore.
- Europe and other emerging markets: Revenue rose 11% to ₹861 crore.
After the results were announced, Cipla’s stock rose by 3.8%, closing at ₹1,543.80 on the BSE.
Read more: Bajaj Finance Falls 6% After Q1 Results: Strong Profit, But MSME Worries Grow; Buy, Sell or Hold?
